Department of Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood vessel Diseases, Beijing 100029, China.
Department of Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood vessel Diseases, Beijing 100029, China.
Clin Chim Acta. 2018 May;480:138-142. doi: 10.1016/j.cca.2018.02.005. Epub 2018 Feb 8.
The aim of this study is to investigate the value of soluble suppression of tumorigenicity 2 (sST2) in Atrial fibrillation (AF) patients' risk prediction.
Healthy people (n = 60) and AF patients (n = 194) were consecutively enrolled into this project.
In the health group, the mean age was 54 y (55% males). Serum median concentration of sST2 in healthy individuals was 17.04 ng/ml. In the AF patients group, the mean age was 61 years, and 64% were males. Median sST2 value was 21.69 ng/ml. According to subgroup analysis, median sST2 value of paroxysmal and persistent AF patients was 19.82 ng/ml and 24.15 ng/ml, respectively. Emergency AF patients showed much higher median sST2 concentration than AF outpatients (41.59 ng/ml vs. 20.53 ng/ml, p < 0.01). By multiple linear regression analysis adjusted for age and sex, heart failure (HF) and BNP strongly associated with sST2 concentration. After healthy people and AF patients with HF excluded, whether emergency visit or not become a patent predictor of sST2 concentration (n = 172).
sST2 is probably an objective biomarker that can predict AF patients' risk of emergency admission or HF. Elevated sST2 concentration may involve in the progression of AF.
本研究旨在探讨可溶性肿瘤抑制因子 2（sST2）在心房颤动（AF）患者风险预测中的价值。
本研究连续纳入了健康人群（n=60）和 AF 患者（n=194）。
在健康组中，平均年龄为 54 岁（55%为男性）。健康个体血清 sST2 中位数浓度为 17.04ng/ml。在 AF 患者组中，平均年龄为 61 岁，64%为男性。sST2 的中位数浓度为 21.69ng/ml。根据亚组分析，阵发性和持续性 AF 患者的 sST2 中位数浓度分别为 19.82ng/ml 和 24.15ng/ml。急诊 AF 患者的 sST2 浓度明显高于门诊 AF 患者（41.59ng/ml vs. 20.53ng/ml，p<0.01）。经年龄和性别调整的多元线性回归分析显示，心力衰竭（HF）和 BNP 与 sST2 浓度密切相关。在排除健康人群和伴有 HF 的 AF 患者后，无论是否为急诊就诊，均可作为 sST2 浓度的预测因子（n=172）。
sST2 可能是一种客观的生物标志物，可预测 AF 患者急诊就诊或 HF 的风险。sST2 浓度的升高可能与 AF 的进展有关。
